Access exclusive insights, data and interviews with Pα+: learn more and subscribe today.

Psychedelics Company Profiles

Click on a company name below to view key financials, press releases and interviews.

ATAI Life Sciences

Beckley Psytech

Better Plant Sciences (PLNT)

CaaMTech

Champignon Brands Inc. (SHRM)

COMPASS Pathways (CMPS)

Cybin Inc.

Eleusis

Entheon Biomedical

Field Trip (FTRP)

Havn Life (HAVN)

Hollister Biosciences (HOLL)

MagicMed Industries

MindMed (MMED)

Mydecine Innovations Group (MYCO)

Numinus (NUMI)

Revive Therapeutics Ltd. (RVV)

Pα+ Psychedelic Bulletin #172: Lykos Scales Back IIT Program, CEO Steps Down; Psyence Scoops Up Clairvoyant for Peanuts; Mindstate’s Moxy Enters Phase ISeptember 9, 2024
Lykos Scales Back Investigator-Initiated Trials Program, Refers Some Researchers to PharmAla • Lykos Appoints ‘Pharma Veterans’ to C-Suite • Psyence Scoops Up Clairvoyant for Peanuts • Mindstate’s Moxy Enters Phase I Trial • Embattled Braxia Bought for $180k • UK Gov. Unveils £400m Plan to Catalyse Clinical Trials • GH Research Waiting on Tox Studies to Respond to FDA’s Clinical Hold • Cydex Sues Bexson Over Psychedelic Salt Patents • and more...
Exclusive: David Hough on Lykos’ Path to ResubmissionSeptember 4, 2024
Josh sits down with the man drafted in by Lykos to plot a path to resubmitting its MDMA application. They talk about Hough’s experience in developing Spravato to eventual approval and how that might inform any future clinical development of MDMA, Hough’s thoughts about the FDA’s verdict and the AdComm that preceded it, what a future Phase 3 program might look like, and more…
Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to Handle Functional Unblinding; Doblin Charts a Future for MAPS; DEA Plots Ketamine CrackdownAugust 30, 2024
Lykos CEO Provides AdComm Feedback to FDA Commissioner • Cybin Plans to Fight Functional Unblinding with ‘Firewall’ • Doblin Charts a Future for MAPS • DEA Plots Ketamine Crackdown • Colorado Closes First Round of Rulemaking for State Psychedelics Program • and more...
What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 2)August 28, 2024
In the second of a two-part series, we look at key trial design features FDA is expected to require of any future Phase 3 study from Lykos. Here, we run through how the MDMA drug developer will be expected to account for euphoria and other ‘positive’ adverse events, address selection bias, and favour larger academic and medical facilities as trial sites over private practices. What’s more, the company might be expected to outsource much of the trial's day-to-day operations.
What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 1)August 22, 2024
As the dust settles on FDA’s decision to not approve Lykos Therapeutics’ MDMA-assisted therapy for PTSD, we look at what the agency expects to see in the fresh Phase 3 study that it requested in its Complete Response Letter. In the first of a two-part series, we look at active placebos and evidence-based psychotherapies.

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.